The data suggest that Sirt3 activator might be a promising candidate for treatment of obese-induced insulin resistance and metabolic diseases, while Sirt3 inhibition might result in insulin resistance and other metabolic dysregulations. The gene discussed is SIRT3; the disease is Insulin resistance.